Design
HAM
REMISSION, MINIMAL RESIDUAL DISEASE
In this multicenter, upfront randomized, open-label, phase II trial, all patients receive quizartinib combined with HAM during salvage therapy. During consolidation therapy (chemotherapy as well as allo-HCT), patients receive either prophylactic quizartinib therapy or MRD-triggered preemptive continuation therapy with quizartinib according to up-front randomization (see Fig. Overall treatment schedule Q-HAM-Study. Abbreviations: MRD, minimal residual disease; CR, complete remission; CRi, complete remission with incomplete hematologic recovery; CRh, complete remission with partial recovery of peripheral blood counts; Q-HAM, quizartinib, high dose cytarabine and mitoxantrone; EOT, end of treatment; EOS, end of study. Please refer to Additional file 